Despite a steep decline in AdVair sales, GlaxoSmithKline Plc was able to report an 11% increase in group revenue to £6.2 billion in the first quarter due to strong demand for its new HIV and respiratory medicines, and its vaccines for meningitis. ---Subscribe to MedNous to access this article--- Company News
